Access to drugs

Find out what changes we're campaigning for to improve treatment options for women with ovarian cancer.

What are we campaigning for? 

Treatment options for ovarian cancer have changed little over the last two decades. Women diagnosed with ovarian cancer are offered a combination of surgery and chemotherapy, or in a very few cases surgery or chemotherapy alone.

Despite some exciting developments in the treatment of ovarian cancer in recent years, such as the availability of bevacizumab (Avastin®), olaparib (Lynparza®) and most recently niraparib (Zejula®), we need to keep campaigning to make sure that all women with ovarian cancer are able to access the best treatment. 

What needs to change? 

It's vital that all women with ovarian cancer have access to new and existing treatments that are right for them, no matter where they live in the UK. 

What has happened so far? 

  • Our campaigners in Northern Ireland helped secure access to niraparib (Zejula®), sending over 200 emails to MLAs when it became available to women with ovarian cancer in the rest of the UK but not Northern Ireland. As a result, women in Northern Ireland can now receive niraparib through the new early access scheme.
  • The Welsh government reviewed the process for accessing drugs on the NHS following campaigning by Target Ovarian Cancer and our campaigners in Wales. Wales now has a New Treatment Fund and women living in Wales can access niraparib (Zejula®) as a result.
  • Our campaigners were instrumental in ensuring that bevacizumab (Avastin®) continued to the available on the Cancer Drugs Fund following reforms in 2016.

Find out about the current situation